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OBJECTIVES: Most health economic models assessing
policies for screening for diabetic nephropathy assume
100% sensitivity and speciﬁcity of screening methods. We
tested the impact considering these factors on cost-
effectiveness of screening for diabetic nephropathy in type
2 diabetes. 
METHODS: A Markov model simulated the progression
of patients from no renal disease, to microalbuminuria
(MAU), to gross proteinuria, and eventually to renal
failure. Data were derived from published sources. Costs
and life expectancy (LE) (discounted at 3% p.a.) and
incremental costs/life year gained (C/LYG) were calcu-
lated for an MAU screening program (treating with ACE
inhibitors if detected) versus no screening assuming 100%
sensitivity and speciﬁcity of the screening method 
(scenario 1), and were compared to those calculated with
more realistic values of sensitivity 71% and speciﬁcity
98% (scenario 2). A US Medicare perspective was taken. 
RESULTS: Costs and LE in a typical type 2 population
for scenario 1 were: $7,047 and 12.70 years in the
screened population, and $11,465 and 12.43 years in the
unscreened population, with screening reducing overall
costs and increasing life expectancy. For scenario 2, costs
and LE in the screened population were $7,303 and 12.66
years, (and remained unchanged in the unscreened popu-
lation). Sensitivity analysis of the sensitivity of screening
showed that at sensitivities below 50%, LE and costs
exponentially approached those of the no screening 
strategy. 
CONCLUSIONS: While affecting the absolute values 
for costs and LE, more realist assumptions about the 
sensitivity and speciﬁcity of screening methods for
nephropathy had little impact on the relative results, 
with a nephropathy screening program dominant to no
screening under both sets of assumption. If sensitivity of
a nephropathy screening test is <50%, sensitivity should
be incorporated in future nephropathy health economic
models assessing screening intervention policies.
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THE DANGER OF IGNORING POPULATION
HETEROGENEITY WHEN MARKOV MODELS ARE
USED FOR COST EFFECTIVENESS ANALYSIS
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OBJECTIVES: To determine the impact of ignoring 
population heterogeneity when Markov models are used
to estimate cost effectiveness ratios. 
METHODS: We constructed a simple Markov model
with three health states: healthy, sick, and dead. We
modeled heterogeneity by assuming that there are two
risk groups (high- and low-risk) differentiated by their
probability of getting sick. We used the Markov model to
estimate the incremental cost effectiveness ratio (ICER) of
a medical intervention that reduces the probability of
becoming sick among high-risk individuals but cannot be
targeted to a single risk group. We used two methods to
estimate the ICER for the intervention: 1. pooling the two
risk groups together into a single homogeneous popula-
tion group; and 2. analyzing the two heterogeneous
groups separately. 
RESULTS: We prove algebraically that the pooled model
always overestimates the number of quality adjusted life
years of survival (QALYs) gained as a result of a medical
intervention. The pooled model may overestimate or
underestimate the incremental costs depending on the
relationships between several parameter values. Thus, 
the pooled model may overestimate or underestimate the
ICER of an intervention. If all costs vary directly in the
amount of time spent in each health state, then both
methods always yield the same ICER. These results can
be extended to Markov models with more than three
health states. 
CONCLUSIONS: Ignoring heterogeneity may lead to
erroneous ICER estimates when Markov models are used
to represent disease progression. Since the sign of the
error depends on several parameters it may be difﬁcult 
to interpret comparisons of the results of modeling
studies. These problems may not be alleviated by 
selecting conservative parameter estimates. The simplify-
ing assumption of combining heterogeneous population
groups should thus be avoided. Policy makers should be
aware of these results when interpreting ICERs estimated
using Markov models.
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OBJECTIVE: The number needed to treat to achieve 
the mortality beneﬁt of HMG-CoA reductase inhibitors
(statins) is substantially lower for secondary prevention
populations when compared to primary prevention 
populations. To determine whether patients with “most
to gain” are more compliant, we compared statin com-
pliance in primary and secondary prevention populations
in a midwestern managed care organization. 
METHODS: Non-Medicaid MCO enrollees who ﬁlled 
≥2 statin prescriptions from January 1998 to November
2001 were included. Administrative data classiﬁed
patients as secondary prevention (diagnosis of AMI or
had undergone PTCA or CABG) or primary prevention
(all others). Compliance was assessed by quantifying the
number of days without medication (cumulative multiple
reﬁll-interval gap [CMG]) for 2 periods: 1) while actively
taking statin (until last ﬁlled prescription ends), and 2)
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until termination (MCO termination, change to non-
statin antihyperlipidemic, or end of observation period). 
RESULTS: Of 4,964 enrollees who received ≥2 statin 
prescriptions, 540 (11%) patients were classiﬁed as 
secondary prevention and 4424 (89%) primary preven-
tion. The mean CMG while actively taking statin was
20.5% (SD 21.5, median 12.7) for the primary group and
21.9% (SD 22.7, median 13.3) for the secondary group
(p = 0.34). The mean CMG until termination was 29.2%
(SD 26.9, median 20.1) and 31.5% (SD 27.3, median
24.6) for the primary and secondary groups respectively
(p = 0.06). Additional analyses will measure the effect 
of patient demographics, copayments, and prescriber 
specialty. 
CONCLUSIONS: Compliance with statins was similar
and sub-optimal in primary and secondary prevention
populations. These data demonstrate that patients exhibit
poor compliance while actively taking therapy and 
contribute to future risk by discontinuing therapy at
undesirable rates. While universal compliance with pre-
scribed therapy for all patients indicated for therapy is a
desirable goal, incremental efforts should aim at improv-
ing compliance in those populations who are the most
likely to beneﬁt from their use.
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OBJECTIVE: The National Cholesterol Education
Program recently recommended the implementation of
interventions to improve compliance with lipid-lowering
medications; however, the costs and beneﬁts of such 
interventions have not been well studied. We therefore
evaluated the cost-effectiveness of compliance-enhancing
interventions in patients treated with HMG Co-A 
reductase inhibitors (statins). 
METHODS: A literature search was conducted to iden-
tify compliance-enhancing interventions that would be
relevant to statin therapy. A Markov model was used 
to evaluate the programs in a hypothetical cohort of 
5000 statin users 65–84 years of age with myocardial 
infarction. Costs and effectiveness of each strategy were
accrued for the duration of treatment, based on published
studies and the assumption of a linear relationship
between compliance and beneﬁts of therapy. Interven-
tions were evaluated in terms of quality-adjusted life years
gained (QALYs), direct medical costs in U.S. dollars, and
incremental cost-effectiveness (cost per QALY gained). 
RESULTS: Seven compliance-enhancing interventions
were evaluated, including combinations of mailed reﬁll
reminders, unit-of-use (“blister-pack”) prescription 
packaging, telephone counseling by a pharmacist, and
pharmacy or clinic-based drug therapy management. We
found that compared to unaided compliance, these 
strategies would yield an average of 0.20 QALYs, with
cost-effectiveness ratios between $17,700 and $36,600
per QALY gained. When compared incrementally, a 
6-month program consisting of mailed educational 
information, reﬁll reminders and a telephone call from a
pharmacist dominated the other strategies, at $17,700 per
QALY gained, compared to no intervention. When base-
line levels of compliance were lowest, the clinic-based
program was the dominant strategy. 
CONCLUSIONS: Compliance-enhancing interventions
appear to be an attractive way to recover some of the 
clinical beneﬁts that are lost due to noncompliance with
statins. For typical populations, the most cost-effective
intervention provided patient education and reﬁll
reminders via the mail and telephone. Clinical trials 
comparing these interventions should be considered to
conﬁrm these results.
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Patients with congestive heart failure (CHF) often are
treated with amiodarone for ventricular or atrial arrhyth-
mias. This agent is often preferred due to its purported
lack of hemodynamic effects, however other toxicities
may occur. Therefore, routine monitoring of lung,
thyroid, and liver function is recommended. Sanoski CA,
et al previously reported that laboratory tests were 
performed according to accepted guidelines in 23% of
patients before referral to an amiodarone clinic compared
to 90% after referral. 
OBJECTIVE: To establish the role for a formal amio-
darone monitoring program in a multidisciplinary CHF
clinic. 
METHODS: After identifying which patients were taking
amiodarone, a retrospective chart review was used to
determine baseline adherence to national guidelines for
performance of chest x-rays, thyroid and liver function. 
RESULTS: Of the 450 patients in the clinic, 47 were
taking amiodarone. Thirty-two patients were male and 
15 female with an average age of 69 + 13 years (53%
ischemic). Indication for amiodarone therapy: 60% atrial
ﬁbrillation/ﬂutter, 21% ventricular tachycardia, 13%
sudden death, 6% unknown. The chart review period was
18.7 + 16.5 months. Baseline analysis revealed annual
chest x-ray in 42.5% of cases; semiannual thyroid func-
tion in 25%; and semiannual liver function in 40%. Of
the 29 patients still taking amiodarone, 52% did not have
a chest x-ray in the previous 12 months, 52% and 34%
